Enzymatica AB (publ) (STO:ENZY)
2.580
+0.080 (3.20%)
May 6, 2026, 5:29 PM CET
Enzymatica AB Revenue
Enzymatica AB had revenue of 11.44M SEK in the quarter ending March 31, 2026, a decrease of -6.84%. This brings the company's revenue in the last twelve months to 53.06M, up 9.56% year-over-year. In the year 2025, Enzymatica AB had annual revenue of 53.90M with 18.27% growth.
Revenue (ttm)
53.06M
Revenue Growth
+9.56%
P/S Ratio
11.44
Revenue / Employee
2.65M
Employees
21
Market Cap
606.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.90M | 8.33M | 18.27% |
| Dec 31, 2024 | 45.58M | -5.33M | -10.47% |
| Dec 31, 2023 | 50.90M | 1.96M | 4.00% |
| Dec 31, 2022 | 48.95M | -8.30M | -14.49% |
| Dec 31, 2021 | 57.24M | -54.00M | -48.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 54.32M |
| Cereno Scientific AB | 44.27M |
| Newbury Pharmaceuticals AB | 32.78M |
| Orexo AB | 17.80M |
| Moberg Pharma AB | 13.54M |
Enzymatica AB News
- 2 months ago - Enzymatica AB Transcript: Stora Aktiedagarna 2026 - Transcripts
- 1 year ago - Enzymatica AB Transcript: Study Result - Transcripts